companydata.dkcompanydata.dk

PHARMA EVIDENCE ApS: Financial statements 2022

CVR: 34586519

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

PHARMA EVIDENCE ApS (CVR 34586519) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 551,989 and a net result of DKK 197,361 compared with DKK -442,484 the year before. That is an increase of 181.6% compared with the year before. Equity in the 2022 report amounted to DKK 1,048,110. The solvency ratio was 82.7%. The company had 1 employee in the financial year.

Gross Profit
DKK 551,989
Profit/Loss
DKK 197,361
Equity
DKK 1,048,110
Total Assets
DKK 1,267,896
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-552 t.197 t.1 mio.1
2021-196 t.-442 t.851 t.1
2020-1.1 mio.643 t.1.3 mio.1
2019-749 t.221 t.650 t.-
2018-1.1 mio.123 t.429 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on PHARMA EVIDENCE ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

PHARMA EVIDENCE ApS: The 2021 annual report is outJun 1, 2022

PHARMA EVIDENCE ApS has published its annual report for 2021. Gross profit came to DKK 196,010, and the net result was DKK -442,484.

About PHARMA EVIDENCE ApS

PHARMA EVIDENCE ApS is a Danish company of the type Anpartsselskab based in Farum, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Tove Holm-Larsen. The company is owned by HB World Holding ApS. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK 64,007 and a net result of DKK 62,147 compared with DKK -179,749 the year before. Equity in the 2025 report amounted to DKK 134,401.

Source: annual report 2025, Danish Business Authority